New Indication for Velcade in Previously Untreated Myeloma
FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma.
FDA has approved Millennium and Takeda’s Velcade (bortezomib) for previously untreated multiple myeloma. “This comes as wonderful news for patients. The VISTA trial showed a 30% complete remission rate with bortezomib compared to 4% for the control arm. Importantly, patients treated with bortezomib also experienced a survival benefit,” said Paul Richardson, MD, senior investigator for the study and clinical director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. For a report on the VISTA study, see ONI March 2008, page 51.
Articles in this issue
National Cancer Survivors Day
New Indication for Velcade in Previously Untreated Myeloma
Risk Factors for Mantle Cell Lymphoma Identified
RAS Mutations Enhance Chemotherapy in AML
Antidiabetic Agent Metformin May Boost pCRs in Breast Ca
Eisai Seeks Full FDA Approval for Ontak for CTCL
Symptom Screen Plus CA125 Detects Early Ovarian Ca
Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Updated X-ACT Study Results Presented
ThromboGenics and BioInvent Announce Alliance with Roche
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Proton beam RT not exempt from evidence-based medicine
Investigational Agents May be Effective for Resistant GIST
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
Recent Videos
Related Content
